drugset
drugset / Trial / NCT04041843

Oral Anticoagulant Apixaban for Treatment of Venous Thromboembolism

NCT04041843 ↗

Phase 2 Completed 25 enrolled New York Medical College
NaSingle-groupOpen-labelTreatment

Summary

Patients who have developed a venous thrombosis will receive apixaban to treat and prevent a secondary thromboembolism.

Timeline

Start
2017-06-02
Primary completion
2021-05-31
Completion
2022-05-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule 5 mg Oral

Indications

venous thromboembolism